Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT

In this retrospective study, we evaluated the benefit of repeated carbon 11 (C11)-acetate positron emission tomography/computed tomography (PET/CT) to assess response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).A total of 30 patients...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicine (Baltimore) 2016-08, Vol.95 (31), p.e4308-e4308
Hauptverfasser: Farnebo, Jacob, Wadelius, Agnes, Sandström, Per, Nilsson, Sten, Jacobsson, Hans, Blomqvist, Lennart, Ullén, Anders
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e4308
container_issue 31
container_start_page e4308
container_title Medicine (Baltimore)
container_volume 95
creator Farnebo, Jacob
Wadelius, Agnes
Sandström, Per
Nilsson, Sten
Jacobsson, Hans
Blomqvist, Lennart
Ullén, Anders
description In this retrospective study, we evaluated the benefit of repeated carbon 11 (C11)-acetate positron emission tomography/computed tomography (PET/CT) to assess response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).A total of 30 patients with mCRPC were monitored with C11-acetate PET/CT and PSA levels during their treatment with AA. Retrospective evaluation of their response was made after 102 days (median; range 70-155) of treatment. Statistical analyses were employed to detect predictors of progression-free survival (PFS) and overall survival (OS), and potential correlation between serum levels of PSA, standardized uptake values (SUVpeak), and bone lesion index measured from PET were investigated.At follow-up 10 patients exhibited partial response (PR), 10 progressive disease (PD), and 10 stable disease (SD), as assessed by PET/CT. In survival analysis, both PR and PD were significantly associated with PFS and OS. CT response was also associated with OS, but only 19/30 patients demonstrated a lesion meeting target lesion criteria according to RECIST 1.1. No PET/CT baseline characteristic was significantly associated with PFS or OS. A PSA response (reduction in the level by >50%) could also predict PFS and OS. In the subgroup lacking a PSA response, those with PD had significantly shorter OS than those with PR or SD.PFS and OS in patients with mCRPC treated with AA can be predicted from repeated C11-acetate PET/CT. This may be of particular clinical value in patients who do not exhibit a PSA response to treatment.
doi_str_mv 10.1097/MD.0000000000004308
format Article
fullrecord <record><control><sourceid>pubmed_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_503302</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>27495034</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5380-5b606dfc0d79c25315415941b1f32b45b5583ae76bac4257cde9caa5598a16893</originalsourceid><addsrcrecordid>eNp1kt1uEzEQhS0EoqHwBEjIL-B2_Le7vkFCaaFIrehFuF55vZPGdLMb2ZtEfSTekknThBYJ33g8c74z0ngY-yjhTIIrz28uzuDZMRqqV2wirS6EdYV5zSYAyorSleaEvcv5F4DUpTJv2YkqjbOgzYT9vk3DXcKc49CLeULkvm_5sMHku47nddrEje947PkSR59HP8bAAwWJIkIIjZTtR75Kw66MVO0DJj4mpFfLt3FccN9EAjANPTUIeNDxBonDNoajMmOK1HAqpTgIby9n59PZe_Zm7ruMH57uU_bz6-VseiWuf3z7Pv1yLYLVFQjbFFC08wBt6YKyWlojrTOykXOtGmMbayvtsSwaH4yyZWjRBe-tdZWXReX0KRN737zF1bqpVykufXqoBx_rp9Q9RVjTADUo0rv_6mkm7V_oAEptQIORFbGf9ywJltgG7Gmu3UuLF5U-Luq7YVMbR99a7Qz03iDQ9HPC-ZGVUO-2pL65qP_dEqI-PW97ZA5rQQKzF2yHjn4t33frLaZ6gb4bF49-tnRKKJAFVKBAUEaB_gMDh818</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SWEPUB Freely available online</source><source>Wolters Kluwer Open Health</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Farnebo, Jacob ; Wadelius, Agnes ; Sandström, Per ; Nilsson, Sten ; Jacobsson, Hans ; Blomqvist, Lennart ; Ullén, Anders</creator><creatorcontrib>Farnebo, Jacob ; Wadelius, Agnes ; Sandström, Per ; Nilsson, Sten ; Jacobsson, Hans ; Blomqvist, Lennart ; Ullén, Anders</creatorcontrib><description>In this retrospective study, we evaluated the benefit of repeated carbon 11 (C11)-acetate positron emission tomography/computed tomography (PET/CT) to assess response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).A total of 30 patients with mCRPC were monitored with C11-acetate PET/CT and PSA levels during their treatment with AA. Retrospective evaluation of their response was made after 102 days (median; range 70-155) of treatment. Statistical analyses were employed to detect predictors of progression-free survival (PFS) and overall survival (OS), and potential correlation between serum levels of PSA, standardized uptake values (SUVpeak), and bone lesion index measured from PET were investigated.At follow-up 10 patients exhibited partial response (PR), 10 progressive disease (PD), and 10 stable disease (SD), as assessed by PET/CT. In survival analysis, both PR and PD were significantly associated with PFS and OS. CT response was also associated with OS, but only 19/30 patients demonstrated a lesion meeting target lesion criteria according to RECIST 1.1. No PET/CT baseline characteristic was significantly associated with PFS or OS. A PSA response (reduction in the level by &gt;50%) could also predict PFS and OS. In the subgroup lacking a PSA response, those with PD had significantly shorter OS than those with PR or SD.PFS and OS in patients with mCRPC treated with AA can be predicted from repeated C11-acetate PET/CT. This may be of particular clinical value in patients who do not exhibit a PSA response to treatment.</description><identifier>ISSN: 0025-7974</identifier><identifier>ISSN: 1536-5964</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000004308</identifier><identifier>PMID: 27495034</identifier><language>eng</language><publisher>United States: The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Abiraterone Acetate - administration &amp; dosage ; Acetates ; Administration, Oral ; Aged ; Antineoplastic Agents - administration &amp; dosage ; Carbon ; Cohort Studies ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Male ; Medicin och hälsovetenskap ; Middle Aged ; Observational Study ; Positron Emission Tomography Computed Tomography - methods ; Predictive Value of Tests ; Prostatic Neoplasms, Castration-Resistant - diagnosis ; Prostatic Neoplasms, Castration-Resistant - drug therapy ; Prostatic Neoplasms, Castration-Resistant - mortality ; Retrospective Studies ; Survival Analysis ; Treatment Outcome</subject><ispartof>Medicine (Baltimore), 2016-08, Vol.95 (31), p.e4308-e4308</ispartof><rights>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.</rights><rights>Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5380-5b606dfc0d79c25315415941b1f32b45b5583ae76bac4257cde9caa5598a16893</citedby><cites>FETCH-LOGICAL-c5380-5b606dfc0d79c25315415941b1f32b45b5583ae76bac4257cde9caa5598a16893</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979788/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979788/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,552,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27495034$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:134030418$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Farnebo, Jacob</creatorcontrib><creatorcontrib>Wadelius, Agnes</creatorcontrib><creatorcontrib>Sandström, Per</creatorcontrib><creatorcontrib>Nilsson, Sten</creatorcontrib><creatorcontrib>Jacobsson, Hans</creatorcontrib><creatorcontrib>Blomqvist, Lennart</creatorcontrib><creatorcontrib>Ullén, Anders</creatorcontrib><title>Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>In this retrospective study, we evaluated the benefit of repeated carbon 11 (C11)-acetate positron emission tomography/computed tomography (PET/CT) to assess response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).A total of 30 patients with mCRPC were monitored with C11-acetate PET/CT and PSA levels during their treatment with AA. Retrospective evaluation of their response was made after 102 days (median; range 70-155) of treatment. Statistical analyses were employed to detect predictors of progression-free survival (PFS) and overall survival (OS), and potential correlation between serum levels of PSA, standardized uptake values (SUVpeak), and bone lesion index measured from PET were investigated.At follow-up 10 patients exhibited partial response (PR), 10 progressive disease (PD), and 10 stable disease (SD), as assessed by PET/CT. In survival analysis, both PR and PD were significantly associated with PFS and OS. CT response was also associated with OS, but only 19/30 patients demonstrated a lesion meeting target lesion criteria according to RECIST 1.1. No PET/CT baseline characteristic was significantly associated with PFS or OS. A PSA response (reduction in the level by &gt;50%) could also predict PFS and OS. In the subgroup lacking a PSA response, those with PD had significantly shorter OS than those with PR or SD.PFS and OS in patients with mCRPC treated with AA can be predicted from repeated C11-acetate PET/CT. This may be of particular clinical value in patients who do not exhibit a PSA response to treatment.</description><subject>Abiraterone Acetate - administration &amp; dosage</subject><subject>Acetates</subject><subject>Administration, Oral</subject><subject>Aged</subject><subject>Antineoplastic Agents - administration &amp; dosage</subject><subject>Carbon</subject><subject>Cohort Studies</subject><subject>Disease-Free Survival</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Medicin och hälsovetenskap</subject><subject>Middle Aged</subject><subject>Observational Study</subject><subject>Positron Emission Tomography Computed Tomography - methods</subject><subject>Predictive Value of Tests</subject><subject>Prostatic Neoplasms, Castration-Resistant - diagnosis</subject><subject>Prostatic Neoplasms, Castration-Resistant - drug therapy</subject><subject>Prostatic Neoplasms, Castration-Resistant - mortality</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0025-7974</issn><issn>1536-5964</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNp1kt1uEzEQhS0EoqHwBEjIL-B2_Le7vkFCaaFIrehFuF55vZPGdLMb2ZtEfSTekknThBYJ33g8c74z0ngY-yjhTIIrz28uzuDZMRqqV2wirS6EdYV5zSYAyorSleaEvcv5F4DUpTJv2YkqjbOgzYT9vk3DXcKc49CLeULkvm_5sMHku47nddrEje947PkSR59HP8bAAwWJIkIIjZTtR75Kw66MVO0DJj4mpFfLt3FccN9EAjANPTUIeNDxBonDNoajMmOK1HAqpTgIby9n59PZe_Zm7ruMH57uU_bz6-VseiWuf3z7Pv1yLYLVFQjbFFC08wBt6YKyWlojrTOykXOtGmMbayvtsSwaH4yyZWjRBe-tdZWXReX0KRN737zF1bqpVykufXqoBx_rp9Q9RVjTADUo0rv_6mkm7V_oAEptQIORFbGf9ywJltgG7Gmu3UuLF5U-Luq7YVMbR99a7Qz03iDQ9HPC-ZGVUO-2pL65qP_dEqI-PW97ZA5rQQKzF2yHjn4t33frLaZ6gb4bF49-tnRKKJAFVKBAUEaB_gMDh818</recordid><startdate>20160801</startdate><enddate>20160801</enddate><creator>Farnebo, Jacob</creator><creator>Wadelius, Agnes</creator><creator>Sandström, Per</creator><creator>Nilsson, Sten</creator><creator>Jacobsson, Hans</creator><creator>Blomqvist, Lennart</creator><creator>Ullén, Anders</creator><general>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20160801</creationdate><title>Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT</title><author>Farnebo, Jacob ; Wadelius, Agnes ; Sandström, Per ; Nilsson, Sten ; Jacobsson, Hans ; Blomqvist, Lennart ; Ullén, Anders</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5380-5b606dfc0d79c25315415941b1f32b45b5583ae76bac4257cde9caa5598a16893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Abiraterone Acetate - administration &amp; dosage</topic><topic>Acetates</topic><topic>Administration, Oral</topic><topic>Aged</topic><topic>Antineoplastic Agents - administration &amp; dosage</topic><topic>Carbon</topic><topic>Cohort Studies</topic><topic>Disease-Free Survival</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Medicin och hälsovetenskap</topic><topic>Middle Aged</topic><topic>Observational Study</topic><topic>Positron Emission Tomography Computed Tomography - methods</topic><topic>Predictive Value of Tests</topic><topic>Prostatic Neoplasms, Castration-Resistant - diagnosis</topic><topic>Prostatic Neoplasms, Castration-Resistant - drug therapy</topic><topic>Prostatic Neoplasms, Castration-Resistant - mortality</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Farnebo, Jacob</creatorcontrib><creatorcontrib>Wadelius, Agnes</creatorcontrib><creatorcontrib>Sandström, Per</creatorcontrib><creatorcontrib>Nilsson, Sten</creatorcontrib><creatorcontrib>Jacobsson, Hans</creatorcontrib><creatorcontrib>Blomqvist, Lennart</creatorcontrib><creatorcontrib>Ullén, Anders</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Farnebo, Jacob</au><au>Wadelius, Agnes</au><au>Sandström, Per</au><au>Nilsson, Sten</au><au>Jacobsson, Hans</au><au>Blomqvist, Lennart</au><au>Ullén, Anders</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2016-08-01</date><risdate>2016</risdate><volume>95</volume><issue>31</issue><spage>e4308</spage><epage>e4308</epage><pages>e4308-e4308</pages><issn>0025-7974</issn><issn>1536-5964</issn><eissn>1536-5964</eissn><abstract>In this retrospective study, we evaluated the benefit of repeated carbon 11 (C11)-acetate positron emission tomography/computed tomography (PET/CT) to assess response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).A total of 30 patients with mCRPC were monitored with C11-acetate PET/CT and PSA levels during their treatment with AA. Retrospective evaluation of their response was made after 102 days (median; range 70-155) of treatment. Statistical analyses were employed to detect predictors of progression-free survival (PFS) and overall survival (OS), and potential correlation between serum levels of PSA, standardized uptake values (SUVpeak), and bone lesion index measured from PET were investigated.At follow-up 10 patients exhibited partial response (PR), 10 progressive disease (PD), and 10 stable disease (SD), as assessed by PET/CT. In survival analysis, both PR and PD were significantly associated with PFS and OS. CT response was also associated with OS, but only 19/30 patients demonstrated a lesion meeting target lesion criteria according to RECIST 1.1. No PET/CT baseline characteristic was significantly associated with PFS or OS. A PSA response (reduction in the level by &gt;50%) could also predict PFS and OS. In the subgroup lacking a PSA response, those with PD had significantly shorter OS than those with PR or SD.PFS and OS in patients with mCRPC treated with AA can be predicted from repeated C11-acetate PET/CT. This may be of particular clinical value in patients who do not exhibit a PSA response to treatment.</abstract><cop>United States</cop><pub>The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>27495034</pmid><doi>10.1097/MD.0000000000004308</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2016-08, Vol.95 (31), p.e4308-e4308
issn 0025-7974
1536-5964
1536-5964
language eng
recordid cdi_swepub_primary_oai_swepub_ki_se_503302
source MEDLINE; DOAJ Directory of Open Access Journals; SWEPUB Freely available online; Wolters Kluwer Open Health; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Abiraterone Acetate - administration & dosage
Acetates
Administration, Oral
Aged
Antineoplastic Agents - administration & dosage
Carbon
Cohort Studies
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Male
Medicin och hälsovetenskap
Middle Aged
Observational Study
Positron Emission Tomography Computed Tomography - methods
Predictive Value of Tests
Prostatic Neoplasms, Castration-Resistant - diagnosis
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - mortality
Retrospective Studies
Survival Analysis
Treatment Outcome
title Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A53%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progression-free%20and%20overall%20survival%20in%20metastatic%20castration-resistant%20prostate%20cancer%20treated%20with%20abiraterone%20acetate%20can%20be%20predicted%20with%20serial%20C11-acetate%20PET/CT&rft.jtitle=Medicine%20(Baltimore)&rft.au=Farnebo,%20Jacob&rft.date=2016-08-01&rft.volume=95&rft.issue=31&rft.spage=e4308&rft.epage=e4308&rft.pages=e4308-e4308&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000004308&rft_dat=%3Cpubmed_swepu%3E27495034%3C/pubmed_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27495034&rfr_iscdi=true